Kexing Biopharm Co., Ltd.

This phase 3 trial tests a long-acting injection called PEG-G-CSF to prevent severe neutropenia (dangerously low white blood cell counts) after chemotherapy in 250 women with breast cancer. Participants receive either the test drug or the already-approved Neulasta. The goal is to…